203 related articles for article (PubMed ID: 10896207)
1. Prognostic value of the expression of tumor suppressor genes p53, p21, p16 and prb, and Ki-67 labelling in high grade astrocytomas treated with radiotherapy.
Kirla R; Salminen E; Huhtala S; Nuutinen J; Talve L; Haapasalo H; Kalimo H
J Neurooncol; 2000; 46(1):71-80. PubMed ID: 10896207
[TBL] [Abstract][Full Text] [Related]
2. Low expression of p27 indicates a poor prognosis in patients with high-grade astrocytomas.
Kirla RM; Haapasalo HK; Kalimo H; Salminen EK
Cancer; 2003 Feb; 97(3):644-8. PubMed ID: 12548606
[TBL] [Abstract][Full Text] [Related]
3. Expression of retinoblastoma gene product and p21 (WAF1/Cip 1) protein in gliomas: correlations with proliferation markers, p53 expression and survival.
Korkolopoulou P; Kouzelis K; Christodoulou P; Papanikolaou A; Thomas-Tsagli E
Acta Neuropathol; 1998 Jun; 95(6):617-24. PubMed ID: 9650754
[TBL] [Abstract][Full Text] [Related]
4. Retinoblastoma protein expression and MIB-1 correlate with survival of patients with malignant astrocytoma.
Nakamura M; Konishi N; Tsunoda S; Hiasa Y; Tsuzuki T; Inui T; Sakaki T
Cancer; 1997 Jul; 80(2):242-9. PubMed ID: 9217037
[TBL] [Abstract][Full Text] [Related]
5. Simultaneous alterations of retinoblastoma and p53 protein expression in astrocytic tumors.
Rathore A; Kamarajan P; Mathur M; Sinha S; Sarkar C
Pathol Oncol Res; 1999; 5(1):21-7. PubMed ID: 10079373
[TBL] [Abstract][Full Text] [Related]
6. Malignant astrocytomas with homozygous CDKN2/p16 gene deletions have higher Ki-67 proliferation indices.
Ono Y; Tamiya T; Ichikawa T; Kunishio K; Matsumoto K; Furuta T; Ohmoto T; Ueki K; Louis DN
J Neuropathol Exp Neurol; 1996 Oct; 55(10):1026-31. PubMed ID: 8857999
[TBL] [Abstract][Full Text] [Related]
7. Cell cycle regulators (p21, p53, pRb) in oligodendrocytic tumors: a study by novel tumor microarray technique.
Miettinen HE; Paunu N; Rantala I; Kalimo H; Paljärvi L; Helin H; Haapasalo H
J Neurooncol; 2001 Oct; 55(1):29-37. PubMed ID: 11804280
[TBL] [Abstract][Full Text] [Related]
8. Prognostic indicators in a range of astrocytic tumours: an immunohistochemical study with Ki-67 and p53 antibodies.
Ellison DW; Steart PV; Bateman AC; Pickering RM; Palmer JD; Weller RO
J Neurol Neurosurg Psychiatry; 1995 Oct; 59(4):413-9. PubMed ID: 7561922
[TBL] [Abstract][Full Text] [Related]
9. Deregulation of the p14ARF/MDM2/p53 pathway is a prerequisite for human astrocytic gliomas with G1-S transition control gene abnormalities.
Ichimura K; Bolin MB; Goike HM; Schmidt EE; Moshref A; Collins VP
Cancer Res; 2000 Jan; 60(2):417-24. PubMed ID: 10667596
[TBL] [Abstract][Full Text] [Related]
10. Role of gemistocytes in astrocytoma progression.
Watanabe K; Tachibana O; Yonekawa Y; Kleihues P; Ohgaki H
Lab Invest; 1997 Feb; 76(2):277-84. PubMed ID: 9042164
[TBL] [Abstract][Full Text] [Related]
11. Roles of the functional loss of p53 and other genes in astrocytoma tumorigenesis and progression.
Nozaki M; Tada M; Kobayashi H; Zhang CL; Sawamura Y; Abe H; Ishii N; Van Meir EG
Neuro Oncol; 1999 Apr; 1(2):124-37. PubMed ID: 11550308
[TBL] [Abstract][Full Text] [Related]
12. Expression of Ki-67, topoisomerase IIalpha and c-MYC in astrocytic tumors: correlation with the histopathological grade and proliferative status.
Faria MH; Gonçalves BP; do Patrocínio RM; de Moraes-Filho MO; Rabenhorst SH
Neuropathology; 2006 Dec; 26(6):519-27. PubMed ID: 17203587
[TBL] [Abstract][Full Text] [Related]
13. Pathways leading to glioblastoma multiforme: a molecular analysis of genetic alterations in 65 astrocytic tumors.
Lang FF; Miller DC; Koslow M; Newcomb EW
J Neurosurg; 1994 Sep; 81(3):427-36. PubMed ID: 8057151
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of molecular markers in low-grade diffuse astrocytomas: loss of p16 and retinoblastoma protein expression is associated with short survival.
Hilton DA; Penney M; Evans B; Sanders H; Love S
Am J Surg Pathol; 2002 Apr; 26(4):472-8. PubMed ID: 11914625
[TBL] [Abstract][Full Text] [Related]
15. Fascin expression [corrected] in glial tumors and its prognostic significance in glioblastomas.
Gunal A; Onguru O; Safali M; Beyzadeoglu M
Neuropathology; 2008 Aug; 28(4):382-6. PubMed ID: 18298442
[TBL] [Abstract][Full Text] [Related]
16. Loss of DCC expression in astrocytomas: relation to p53 abnormalities, cell kinetics, and survival.
Hara A; Saegusa M; Mikami T; Okayasu I
J Clin Pathol; 2001 Nov; 54(11):860-5. PubMed ID: 11684721
[TBL] [Abstract][Full Text] [Related]
17. Accumulation of p53 and Ki-67 expression do not predict survival in patients with fibrillary astrocytomas or the response of these tumors to radiotherapy.
Hilton DA; Love S; Barber R; Ellison D; Sandeman DR
Neurosurgery; 1998 Apr; 42(4):724-9. PubMed ID: 9574635
[TBL] [Abstract][Full Text] [Related]
18. CDKN2/p16 inactivation and p16 immunohistochemistry in astrocytic gliomas.
Piva R; Cavalla P; Bortolotto S; Cordera S; Grosso R; Richiardi P; Dutto A; Schiffer D
Int J Oncol; 1998 Jan; 12(1):55-8. PubMed ID: 9454886
[TBL] [Abstract][Full Text] [Related]
19. Accumulation of wild-type p53 in astrocytomas is associated with increased p21 expression.
Ono Y; Tamiya T; Ichikawa T; Matsumoto K; Furuta T; Ohmoto T; Akiyama K; Seki S; Ueki K; Louis DN
Acta Neuropathol; 1997 Jul; 94(1):21-7. PubMed ID: 9224526
[TBL] [Abstract][Full Text] [Related]
20. Manganese superoxide dismutase (MnSOD) is a malignant astrocytoma specific biomarker and associated with adverse prognosis in p53 expressing glioblastoma.
Shwetha SD; Shastry AH; Arivazhagan A; Santosh V
Pathol Res Pract; 2016 Jan; 212(1):17-23. PubMed ID: 26616112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
